Who owns ABEONA THERAPEUTICS INC. (ABEO)? Elite investor 13F holders

2 tracked elite investors reported holding ABEONA THERAPEUTICS INC as of 2026-09-30, including Rubric Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Rubric CapitalABEONA THERAPEUTICS INCSHARE2026-09-302026-11-16 00:00:0017533462.00 USD3339707.000000SharesaddOriginal filing
D.E. ShawABEONA THERAPEUTICS INCSHARE2026-09-302026-11-16 00:00:0061016.00 USD11622.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown